Featured Research

from universities, journals, and other organizations

Novel therapeutic target for the treatment of Huntington’s disease

Date:
July 23, 2010
Source:
Universidad de Barcelona
Summary:
New research suggests a novel pharmacological target that, in combination with a neurotrophic factor, could be used to improve the survival of striatal neurons, the principal nerve cells affected by the neurodegeneration observed in Huntington’s disease.

PMA treatment restores ERK1/2 pathway activation and prevents cell injury induced by Huntington disease.
Credit: Image courtesy of Universidad de Barcelona

An article published in The Journal of Biological Chemistry presents a novel pharmacological target that, in combination with a neurotrophic factor, could be used to improve the survival of striatal neurons, the principal nerve cells affected by the neurodegeneration observed in Huntington's disease.

Related Articles


The study was conducted by the researchers Silvia Ginιs, a lecturer in the University of Barcelona; and Paola Paoletti, a doctoral student and Jordi Alberch professor with the Department of Cell Biology, Immunology and Neurosciences in the Faculty of Medicine in the UB.

Huntington's chorea is a progressive neurodegenerative disease caused by a genetic mutation of the gene encoding for the protein Huntingtin. The disease principally affects the basal ganglia, which regulate motor control and other important functions. One of the most widely studied potential therapeutic targets for the treatment of Huntington's disease is the brain-derived neurotrophic factor (BDNF), essential in the survival of striatal neurons and severely depleted in Huntington's sufferers. The researchers used an in vitro cell model to study whether the cells that express the mutated Huntingtin respond to administration of BDNF. "We concluded that treatment with BDNF is an effective therapeutic strategy for this disease, but that combined treatments are probably needed to modulate different aspects of the pathology," explains the UB researcher Silvia Ginιs, who is also a researcher for the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and the Networked Biomedical Research Centre for Neurodegenerative Diseases (CIBERNED).

In order to act, the neurotrophic factor BDNF must bind to the catalytic receptor TrkB, levels of which are also reduced in Huntington's disease. The receptor is the key to activating signalling of the three pathways involved in the survival of the striatal neurons. The researchers reproduced the conditions of the disease and induced oxidative stress, which alters the metabolism of the nerve cells and affects their DNA. They found that under oxidative stress, two of the pathways function correctly when BDNF is administered but the third (MAPK/ERK1/2) does not. To improve the treatment response, the team used the activator PMA, a phorbol ester of which scientists are trying to find a suitable human analogue. The next step in the research, as Silvia Ginιs explains, is to find "modulators of the third pathway (MAPK/ERK1/2) as a possible final treatment and possibly even to develop a strategy for modulating the receptor itself to increase the efficiency of the response."

Although the genetic mutation affects the whole body to some degree its principal impact is on the brain, where it causes severe degeneration of the striatal neurons as well as a lesser degree of generation in the cerebral cortex and the hippocampus. Huntington's patients cannot coordinate their movements and are affected by uncontrollable contractions known as chorea, making it difficult for them to lead a normal life. Researchers are also studying the molecular mechanisms contributing to the cognitive defects observed in the initial stages of the disease, which are known to cause alterations of executive memory, thus affecting the sufferer's ability to complete or organize simple everyday tasks.


Story Source:

The above story is based on materials provided by Universidad de Barcelona. Note: Materials may be edited for content and length.


Journal Reference:

  1. Silvia Gines, Paola Paoletti and Jordi Alberch. Impaired TrkB-mediated ERK1/2 Activation in Huntington Disease Knock-in Striatal Cells Involves Reduced p52/p46 Shc Expression. Journal of Biological Chemistry, 2010; DOI: 10.1074/jbc.M109.08420

Cite This Page:

Universidad de Barcelona. "Novel therapeutic target for the treatment of Huntington’s disease." ScienceDaily. ScienceDaily, 23 July 2010. <www.sciencedaily.com/releases/2010/07/100723075958.htm>.
Universidad de Barcelona. (2010, July 23). Novel therapeutic target for the treatment of Huntington’s disease. ScienceDaily. Retrieved April 18, 2015 from www.sciencedaily.com/releases/2010/07/100723075958.htm
Universidad de Barcelona. "Novel therapeutic target for the treatment of Huntington’s disease." ScienceDaily. www.sciencedaily.com/releases/2010/07/100723075958.htm (accessed April 18, 2015).

Share This


More From ScienceDaily



More Mind & Brain News

Saturday, April 18, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Our Love Of Puppy Dog Eyes Explained By Science

Our Love Of Puppy Dog Eyes Explained By Science

Newsy (Apr. 17, 2015) — Researchers found a spike in oxytocin occurs in both humans and dogs when they gaze into each other&apos;s eyes. Video provided by Newsy
Powered by NewsLook.com
Scientists Find Link Between Gestational Diabetes And Autism

Scientists Find Link Between Gestational Diabetes And Autism

Newsy (Apr. 17, 2015) — Researchers who analyzed data from over 300,000 kids and their mothers say they&apos;ve found a link between gestational diabetes and autism. Video provided by Newsy
Powered by NewsLook.com
Video Messages Help Reassure Dementia Patients

Video Messages Help Reassure Dementia Patients

AP (Apr. 17, 2015) — Family members are prerecording messages as part of a unique pilot program at the Hebrew Home in New York. The videos are trying to help victims of Alzheimer&apos;s disease and other forms of dementia break through the morning fog of forgetfulness. (April 17) Video provided by AP
Powered by NewsLook.com
Common Pain Reliever Might Dull Your Emotions

Common Pain Reliever Might Dull Your Emotions

Newsy (Apr. 16, 2015) — Each week, millions of Americans take acetaminophen to dull minor aches and pains. Now researchers say it might blunt life&apos;s highs and lows, too. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins